Audeara launches US OTC listing process on back of record FY26 revenue
Audeara Limited (ASX: AUA) has formally commenced the process to establish a quotation on the OTCID tier of the US Over-the-Counter market, following a record FY26 Group revenue result of approximately $4.45 million. The initiative involves no capital raising and no new securities, meaning existing shareholders face no dilution. Proposed quotation is expected within 6–8 weeks, subject to application, eligibility review and acceptance by OTC Markets, with the ASX remaining Audeara’s primary listing and home market.
When big ASX news breaks, our subscribers know first
Record FY26 revenue sets the stage
Audeara’s FY26 Group revenue reached approximately $4.45 million, a record result for the company. North America contributed approximately $1.56 million of that total, establishing the region as a material commercial market.
AUA Technology generated approximately $1.68 million in revenue during FY26, while the first two OPTEK customer programs incorporating Audeara’s proprietary AI audio technology progressed to commercial production during the period.
The OPTEK AI chip licensing program reached commercial production across two customer programs during FY26, deploying Audeara’s audio algorithms directly on third-party semiconductor platforms through a fee-per-chip model that scales revenue without adding manufacturing costs.
Key FY26 revenue metrics at a glance:
- Group revenue: approximately $4.45m (record)
- North America: approximately $1.56m
- AUA Technology: approximately $1.68m
- OPTEK programs: reached commercial production
The result reflects Audeara’s commercial pivot beyond audio hardware into a broader model spanning hearing health, connected devices, embedded software and AI-enabled audio processing.
CEO commentary
Dr James Fielding, Managing Director and Chief Executive Officer
“FY26 was an important year for Audeara. We delivered record revenue, materially improved operating cash flow and saw our technology increasingly move from development into commercial deployment… we now operate across hearing health, connected devices, embedded software and AI-enabled audio processing.”
What is OTC quotation and why does it matter for investors?
The US Over-the-Counter (OTC) market is a decentralised marketplace where securities not listed on major US exchanges such as the New York Stock Exchange or NASDAQ can be traded by US-based investors. It operates through a network of broker-dealers rather than a centralised exchange floor.
The OTCID tier is specifically designed for international companies already listed on a recognised foreign exchange, such as the ASX. It provides a structured pathway for those companies to make their securities accessible to US investors without requiring a full US exchange listing.
For ASX-listed retail investors, the practical significance is straightforward. US-based investors often encounter friction when attempting to access foreign-listed securities directly. An OTCID quotation creates a more familiar and accessible trading pathway for that investor base, which can broaden awareness and liquidity over time. Importantly, no new Audeara securities are created as part of this process — existing ASX-listed shares are simply quoted on the OTC platform.
To manage the process end-to-end, Audeara has appointed Viriathus Capital LLC Series as its non-exclusive Financial Advisor for an initial three-month engagement. Viriathus will oversee eligibility review, application preparation, liaison with OTC Markets Group, and engagement with the relevant market maker.
Strategic rationale and what comes next
With approximately $1.56 million in North American revenue already recorded in FY26, the US market represents a meaningful and growing part of Audeara’s commercial base. The OTC initiative is positioned as a logical progression: building US investor awareness to match the commercial activity already taking place in the region.
Clinico white-label programs have been a material contributor to Audeara’s North American commercial footprint, with $164,000 in purchase orders placed across three programs incorporating the BT-03 Audio Broadcaster technology, building on an initial Taiwan pilot from late 2024.
The structure is investor-friendly. No new shares are issued, no capital is raised, and the ASX remains the primary listing. If approved, the quotation would simply widen the pool of investors able to access Audeara securities through a familiar US trading pathway.
The key next steps in the process are:
- Preparation of the application and eligibility review
- Liaison with OTC Markets Group and the relevant market maker, managed by Viriathus
- Proposed quotation expected within 6–8 weeks
- Audeara will update the market if and when quotation is approved and trading is able to commence
It should be noted that quotation remains subject to completion of the application process, eligibility review and acceptance by OTC Markets. There is no guarantee that quotation will be approved.
If approved, an OTCID quotation would position Audeara to reach US technology and healthcare investors at a time when its AI audio and hearing health technology platforms are gaining commercial traction.
| Detail | Description |
|---|---|
| Listing tier | OTCID (US Over-the-Counter market, international company tier) |
| Advisor appointed | Viriathus Capital LLC Series (non-exclusive Financial Advisor, initial three-month engagement) |
| Capital raise involved | No — no new securities issued, no dilution to existing shareholders |
| Timeline | Proposed quotation expected within 6–8 weeks, subject to OTC Markets approval |
| Primary listing | ASX remains Audeara’s primary listing and home market |
I notice that no Target URL was provided in your input. Could you please share the Target URL you’d like embedded in the CTA? Once you provide it, I’ll generate the complete output immediately.